AO 120 (Rev. 08/10)

TO:

Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK

| ☐ Trademarks or | \square Patents. (\square the patent act | ion involves 35 U.S.C. § 292.): | |
|----------------------------|---|---|--|
| OCKET NO. | DATE FILED | U.S. DISTRICT COURT | |
| LAINTIFF | _ | DEFENDANT | |
| PATENT OR TRADEMARK NO. | DATE OF PATENT OR TRADEMARK | HOLDER OF PATENT OR TRADEMARK | |
| | | | |
| | | | |
| | | | |
| | | | |
| | In the above—entitled case, the | e following patent(s)/ trademark(s) have been included: | |
| ATE INCLUDED PATENT OR | INCLUDED BY | endment Answer Cross Bill Other Pleading | |
| PATENT OR TRADEMARK NO. | INCLUDED BY | | |
| PATENT OR | INCLUDED BY Ame DATE OF PATENT | endment Answer Cross Bill Other Pleading | |
| PATENT OR TRADEMARK NO. | INCLUDED BY Ame DATE OF PATENT | endment Answer Cross Bill Other Pleading | |
| PATENT OR TRADEMARK NO. | INCLUDED BY Ame DATE OF PATENT | endment Answer Cross Bill Other Pleading | |
| PATENT OR TRADEMARK NO. | INCLUDED BY Ame DATE OF PATENT | endment Answer Cross Bill Other Pleading | |
| PATENT OR TRADEMARK NO. | INCLUDED BY DATE OF PATENT OR TRADEMARK | endment | |
| PATENT OR TRADEMARK NO. | INCLUDED BY DATE OF PATENT OR TRADEMARK | endment Answer Cross Bill Other Pleading | |



ATTACHMENT A

Patents

| Patent No. | Date of Patent | Holder of Patent |
|------------|-------------------|-------------------------|
| 8,058,069 | November 15, 2011 | Arbutus Biopharma Corp. |
| 8,492,359 | July 23, 2013 | Arbutus Biopharma Corp. |
| 8,822,668 | September 2, 2014 | Arbutus Biopharma Corp. |
| 9,006,417 | April 14, 2015 | Arbutus Biopharma Corp. |
| 9,364,435 | June 14, 2016 | Arbutus Biopharma Corp. |
| 9,404,127 | August 2, 2016 | Arbutus Biopharma Corp. |
| 9,504,651 | November 29, 2016 | Arbutus Biopharma Corp. |
| 9,518,272 | December 13, 2016 | Arbutus Biopharma Corp. |
| 11,141,378 | October 12, 2021 | Arbutus Biopharma Corp. |